[1] Xu X, Wang G, Chen N, et al.Long-term exposure to air pollution and increased risk of membranous nephropathy in China[J]. J Am Soc Nephrol,2016,27(12):3739-3746.
[2] Stanescu HC, Arcos-Burgos M, Medlar A, et al.Risk HLA-DQA1 and PLA(2)R1 alleles in idiopathic membranous nephropathy[J]. N Engl J Med,2011,364(7):616-626.
[3] Lv J, Hou W, Zhou X, et al.Interaction between PLA2R1 and HLA-DQA1 variants associates with anti-PLA2R antibodies and membranous nephropathy[J]. J Am Soc Nephrol,2013,24(8):1323-1329.
[4] Honkanen E, Törnroth T, Grönhagen-Riska C. Natural history, clinical course and morphological evolution of membranous nephropathy[J]. Nephrol Dial Transplant,1992,7 Suppl 1:35-41.
[5] Lionaki S, Derebail VK, Hogan SL, et al.Venous thromboembolism in patients with membranous nephropathy[J]. Clin J Am Soc Nephrol,2012,7(1):43-51.
[6] Tomas NM, Beck LH Jr, Meyer-Schwesinger C, et al.Thrombospondin type-1 domain-containing 7A in idiopathic membranous nephropathy[J]. N Engl J Med, 2014, 371(24):2277-2287.
[7] Beck LH Jr, Bonegio RG, Lambeau G, et al.M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy[J]. N Engl J Med,2009,361(1):11-21.
[8] De Vriese AS, Glassock RJ, Nath KA, et al.A Proposal for a serology-based approach to membranous nephropathy[J]. J Am Soc Nephrol,2017,28(2):421-430.
[9] Timmermans SA, Damoiseaux JG, Heerings-Rewinkel PT, et al.Evaluation of anti-PLA2R1 as measured by a novel ELISA in patients with idiopathic membranous nephropathy: a cohort study[J]. Am J Clin Pathol,2014,142(1):29-34.
[10] Du Y, Li J, He F, et al.The diagnosis accuracy of PLA2R-AB in the diagnosis of idiopathic membranous nephropathy: a meta-analysis[J]. PLoS One,2014,9(8): e104936.
[11] Dai H, Zhang H, He Y.Diagnostic accuracy of PLA2R autoantibodies and glomerular staining for the differentiation of idiopathic and secondary membranous nephropathy: an updated meta-analysis[J]. Sci Rep, 2015, 5: 8803.
[12] Hoxha E, Beck LH Jr, Wiech T, et al.An Indirect immunofluorescence method facilitates detection of thrombospondin type 1 domain-containing 7A-specific antibo-dies in membranous nephropathy[J]. J Am Soc Nephrol,2017,28(2):520-531.
[13] Hoxha E, Wiech T, Stahl PR, et al.A Mechanism for Cancer-Associated Membranous Nephropathy[J]. N Engl J Med,2016,374(20):1995-1996.
[14] Stahl PR, Hoxha E, Wiech T, et al.THSD7A expression in human cancer[J]. Genes Chromosomes Cancer,2017, 56(4):314-327.
[15] Hofstra JM, Beck LH Jr, Beck DM, et al.Anti-phospholipase A2 receptor antibodies correlate with clinical status in idiopathic membranous nephropathy[J]. Clin J Am Soc Nephrol,2011,6(6):1286-1291.
[16] Quintana LF, Blasco M, Seras M, et al.Antiphospholipase A2 receptor antibody levels predict the risk of posttransplantation recurrence of membranous nephropathy[J]. Transplantation, 2015, 99(8):1709-1714.
[17] Tomas NM, Hoxha E, Reinicke AT, et al.Autoantibodies against thrombospondin type 1 domain-containing 7A induce membranous nephropathy[J]. J Clin Invest,2016, 126(7):2519-2532.
[18] Pei Y, Cattran D, Greenwood C.Predicting chronic renal insufficiency in idiopathic membranous glomerulonephritis[J]. Kidney Int,1992,42(4):960-966.
[19] Tse WY, Howie AJ, Adu D, et al.Association of vasculitic glomerulonephritis with membranous nephropathy: a report of 10 cases[J]. Nephrol Dial Transplant,1997,12(5):1017-1027.
[20] Nasr SH, Said SM, Valeri AM, et al.Membranous glomerulonephritis with ANCA-associated necrotizing and crescentic glomerulonephritis[J]. Clin J Am Soc Nephrol, 2009,4(2):299-308.
[21] Lefaucheur C, Stengel B, Nochy D, et al.Membranous nephropathy and cancer: Epidemiologic evidence and determinants of high-risk cancer association[J]. Kidney Int, 2006,70(8):1510-1517. |
